title: Gastroduodenal Crohn's disease: medical management.
authors.affiliation: Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA. tremaine.william@mayo.edu
authors.forename: William J
authors.initials: WJ
authors.lastname: Tremaine
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D004359:Drug Therapy, Combination; D004382:Duodenitis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects* / Q000473:pathology; D005756:Gastritis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D005765:Gastrointestinal Agents / Q000008:administration & dosage*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D000069285:Infliximab; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000473:pathology; D008134:Long-Term Care; D008297:Male; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000897:Anti-Ulcer Agents; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents; D000069285:Infliximab